Abstract 841P
Background
Although several clinical parameters-based prediction indexes of extra-nodal natural killer/T-cell lymphoma (ENKTL) are proposed, these indexes include none of pathological index and had insufficient accuracy. A superior clinically feasible prediction index for ENKTL in the modern chemotherapy era is warranted.
Methods
600 ENKTL patients receiving non-anthracycline based therapy from Sun Yat-sen University Cancer Center were subdivided into training and internal validation datasets. An external validation dataset included 191 patients from West China Hospital was enrolled. Ki67 proliferative index and 14 pretreatment clinical parameters were tested against overall survival (OS) and progression-free survival (PFS). A prediction model was constructed and validated.
Results
Factors independently associated with inferior OS were as follows: Ki67 ≥ 70%; age > 60 years; ECOG PS ≥ 2; B symptoms; stage-III/-IV disease and detectable EBV-DNA copy number. Each of these six factors contributed one point to a prediction model that stratified patients into four risk groups: 0-1 point, low-risk; 2 points, intermediate-risk;3 points, intermediate high-risk; 4-6 points, high-risk. In the training dataset, the 5-year OS rates were 91%, 75%, 65% and 26% for the low-, intermediate-, intermediate high- and high-risk group, respectively (P < 0.001). The 5-year PFS rates were 79%, 62%, 48% and 15%, respectively (P < 0001). The time-dependent area under the receiver-operator characteristic (AUROC) curve and Harrell’s C-statistic of Ki67-revised Risk Index (KRI) for OS and PFS prediction demonstrated a better performance than that of the international prognostic index (IPI), Korean prognostic index (KPI), prognostic index of natural killer lymphoma (PINK) and nomogram-revised risk index (NRI). Concordant results were successfully validated in both internal and external validation datasets.
Conclusions
KRI is a new promising prediction index to risk-stratify patients with ENKTL receiving non-anthracycline based therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18